Delayed-Onset Cariprazine-Induced Akathisia: A Case Report

Abstract/Description/Artist Statement

Objective 

This case report describes the clinically underrecognized manifestation of delayed-onset akathisia induced by cariprazine occurring 10 weeks after treatment initiation. The secondary objective was to discuss potential pharmacokinetic and pharmacodynamic mechanisms of the drug-induced side effect.

Methods

A retrospective review of the patient’s medical and psychiatric history was performed in addition to a comprehensive literature review.

Results

A 42-year-old female with bipolar disorder and generalized anxiety disorder presented to the emergency department on three separate occasions with severe restlessness and insomnia commonly attributed to her previous history of anxiety. Although initial treatment with lorazepam provided subjective symptom relief, the underlying cause persisted. Psychiatry consultation led to a diagnosis of antipsychotic-induced akathisia and administration of diphenhydramine resulted in rapid improvement. The offending agent, cariprazine, was discontinued, resulting in sustained symptom resolution.

Conclusions 

This case highlights the challenge of distinguishing akathisia from primary anxiety disorders, in addition to considering this diagnosis beyond the initial treatment period. Akathisia symptoms most commonly present within four weeks of initiation or titration of antidopaminergic treatment. However, this timeline may be delayed with cariprazine due to its pharmacokinetic and pharmacodynamic properties.

Presenting Author Name/s

Zachary Goodrich

Faculty Advisor/Mentor

Drew Grehan

Faculty Advisor/Mentor Email

grehandk@odu.edu

Faculty Advisor/Mentor Department

Psychiatry

College/School Affiliation

Eastern Virginia School of Medicine

Student Level Group

Medical

Presentation Type

Poster

This document is currently not available here.

Share

COinS
 

Delayed-Onset Cariprazine-Induced Akathisia: A Case Report

Objective 

This case report describes the clinically underrecognized manifestation of delayed-onset akathisia induced by cariprazine occurring 10 weeks after treatment initiation. The secondary objective was to discuss potential pharmacokinetic and pharmacodynamic mechanisms of the drug-induced side effect.

Methods

A retrospective review of the patient’s medical and psychiatric history was performed in addition to a comprehensive literature review.

Results

A 42-year-old female with bipolar disorder and generalized anxiety disorder presented to the emergency department on three separate occasions with severe restlessness and insomnia commonly attributed to her previous history of anxiety. Although initial treatment with lorazepam provided subjective symptom relief, the underlying cause persisted. Psychiatry consultation led to a diagnosis of antipsychotic-induced akathisia and administration of diphenhydramine resulted in rapid improvement. The offending agent, cariprazine, was discontinued, resulting in sustained symptom resolution.

Conclusions 

This case highlights the challenge of distinguishing akathisia from primary anxiety disorders, in addition to considering this diagnosis beyond the initial treatment period. Akathisia symptoms most commonly present within four weeks of initiation or titration of antidopaminergic treatment. However, this timeline may be delayed with cariprazine due to its pharmacokinetic and pharmacodynamic properties.